Obalon Corporate

Weight loss technology based on the principle that less is more.

Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. As a company, we believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.

Extraordinarily experienced in healthcare innovation.

Kelly Huang, Ph.D., has served as our Chief Executive Officer since January 2019. He was Chief Operating Officer starting in September 2017 and was promoted to President in August 2018. Prior to joining Obalon, Dr. Huang was the General Manager for Galderma Laboratories, L.P., Aesthetic & Corrective, where he led business strategy, execution, and development. Prior to Galderma, Dr. Huang was a President of Endo Pharmaceutical’s Executive Committee, responsible for leadership of the urology device and services division. Dr. Huang was also at Johnson & Johnson for more than 16 years, across a variety of divisions, from research and development to professional sales and marketing.
William J. Plovanic has served as our Chief Financial Officer since March 2016. Prior to joining Obalon, Mr. Plovanic worked for 20 years as an equity research analyst covering medical device companies. From February 2007 to March 2016, Mr. Plovanic served as a Managing Director, Medical Technology Equity Research Analyst at CanaccordGenuity, Inc., a global, full-service investment bank.
Mark Brister has served as our Vice President of Research and Development since June 2008. Mr. Brister has an extensive history of developing novel technology platforms that have served as the foundation for creating successful companies. Mr. Brister was Vice President of R&D for DexCom, Inc., Vice President of Vascular R&D for Medtronic, Inc., and Vice President of R&D for Arterial Vascular Engineering.
Amy VandenBerg has served as our Chief Clinical & Regulatory Affairs Officer since December 2018. Ms. VandenBerg joined Obalon in 2008 as Director of Regulatory Affairs. Ms. VandenBerg has served as our Vice President of Regulatory Affairs since February 2012 and assumed the Vice President of Clinical and Regulatory Affairs position in November 2014. Prior to joining Obalon, Ms. VandenBerg held positions of increasing leadership at other medical device companies, including Dexcom, Inc. (NASDAQ:DXCM) and Cygnus. She has more than 20 years of experience with a focus on medical device quality systems, clinical affairs as well as domestic and international regulatory affairs in bringing novel and disruptive medical device technologies from the research and development phase through the US FDA PMA approval process.
Neil Drake has focused his career for the last twenty years on new, novel technology in the class III implantable medical device industry. Previous companies include Arterial Vascular Engineering, Medtronic Vascular, and Dexcom. He's held positions of increasing responsibilities and leadership in manufacturing engineering, quality engineering, and R&D leading up to his current position of VP of Engineering with Obalon Therapeutics. He holds several patents and was one of the original developers of the Obalon Balloon System.
Nooshin Hussainy has served as our Vice President of Finance since December 2011. Ms. Hussainy has over 20 years of experience in high growth companies ranging from Fortune 100 to venture-backed start-ups, including DexCom, Inc., GenMark Diagnostics, and Active Network. Ms. Hussainy has completed 2 IPOs in medical devices and diagnostics, secondary offerings, and debt offerings.
Bob Mondore has served as our Vice President of Operations since April 2018. Mr. Mondore brings more than 20 years of experience in medical device operations across a broad range of devices including surgical drills, orthopedic implants, cochlear implants and gastrointestinal devices. Prior to joining Obalon, Mr. Mondore led multiple plants at Medtronic and Advanced Bionics. His earlier experience includes positions of increasing responsibilities in supply chain, engineering and manufacturing at Orthofix and Medtronic Sofamor Danek.
Daina Schmidt, has served as our Vice President of Marketing since October 2018. Prior to joining Obalon, Ms. Schmidt was Senior Director of Marketing at Syneron Candela. Prior to that she was with Valeant as Sr. Director for Obagi, a position she transitioned to following Valeant's acquisition of Bausch + Lomb, where she was the Executive Director of Global Marketing for the cataract business. Ms. Schmidt also held positions at Allergan from 2002 to 2011, including Senior Director of Global Marketing for Allergan's breast implant business.

Visionaries with track records of success.

Andrew Rasdal has served as a member of our board of directors and as our President and Chief Executive Officer since June 2008. Mr. Rasdal brings more than 25 years of medical technology experience, including serving as CEO of DexCom, Inc., Senior Vice President and President of Vascular for Medtronic, Inc., and Vice President of Marketing for Arterial Vascular Engineering.
Raymond Dittamore has served as a member of our board of directors since March 2016. Mr. Dittamore retired in June 2001 as a partner of Ernst & Young LLP, an international public accounting firm, after 35 years of service. Mr. Dittamore currently serves on the board of directors of QUALCOMM Incorporated, a semiconductor and telecommunications equipment company. Mr. Dittamore previously served on the boards of directors of Life Technologies Corporation, Gen-Probe Incorporation and Digirad Corporation.
David Moatazedi has served as a member of our board since March 2017. Mr. Moatazedi is currently Senior Vice President, U.S. Medical Aesthetics including Facial Aesthetics, Plastic Surgery and Regenerative Medicine, Body Contouring and Skincare, for Allergan plc, where he has worked in positions of increasing responsibility since March 2005. Prior to Allergan, Mr. Moatazedi held several positions at Novartis Pharmaceuticals, including District Manager from June 2002 to March 2005.
Douglas Fisher has served as a member of our board since May 2012. Dr. Fisher is currently an Executive in Residence at InterWest Partners LLC, a venture capital firm, where he has worked since March 2009. Dr. Fisher also serves as the Chief Business Officer at Sera Prognostics, Inc., where he has worked since January 2015. Prior to joining InterWest, Dr. Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and venture capital firm, from January 2006 to March 2009. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm, from November 2003 to February 2006.
Les Howe has served as a member of our board of directors since January 2016. Mr. Howe served as the Chief Executive Officer of Consumer Networks LLC, an internet marketing and promotions company, from December 2001 to May 2007. From July 1967 to September 1997, Mr. Howe held several positions at KPMG Peat Marwick LLP, an international auditing and accounting firm, and served as area managing partner/managing partner of their Los Angeles office from May 1994 to September 1997.
Kim Kamdar, Ph.D. has served as a member of our board of directors since January 2008. Dr. Kamdar is currently a partner at Domain Associates, LLC, a venture capital firm, where she has worked since 2005. Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital, as well as a research director at Novartis International AG.
Sharon Stevenson, DVM Ph.D. has served as a member of our board since January 2008. Dr. Stevenson is currently a Co-Founder and Managing Director of Okapi Venture Capital, a venture capital company, where she has worked since 2005. Prior to founding Okapi, Dr. Stevenson was the Senior Vice President of Technology and Planning for SkinMedica, Inc. (acquired by Allergan, Inc.) from 2003 to 2004. Prior to SkinMedica, Dr. Stevenson was a Principal with Domain Associates, LLC from 2000 to 2003. While at Domain, Dr. Stevenson also served as President and Chief Financial Officer of Volcano Corporation.

Deeply engaged in advancing healthcare.

Obalon Therapeutics, Inc was founded in 2008 and is backed by the following:

  • Domain Associates
  • InterWest Partners
  • Okapi Venture Capital
  • AmorePacific
  • Axon Ventures
  • Bader Sultan & Bros. Co. W.L.L.
  • Mirae Asset Venture Investment
  • NeoPlux Co., Ltd.
  • Striker Asia Opportunities Fund
  • Square 1 Bank
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click on Safety Information and Patient Labeling.